company background image
SHE logo

Shedir Pharma Group BIT:SHE Stock Report

Last Price

€4.88

Market Cap

€55.4m

7D

0%

1Y

8.0%

Updated

24 Jan, 2025

Data

Company Financials +

Shedir Pharma Group S.p.A.

BIT:SHE Stock Report

Market Cap: €55.4m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

SHE Stock Overview

Through its subsidiaries, engages in the research, formulation, development, and marketing of nutraceuticals, dermocosmetics, medical devices, and pharmaceutical products in Italy. More details

SHE fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance2/6
Financial Health6/6
Dividends3/6

My Notes

Capture your thoughts, links and company narrative

Shedir Pharma Group S.p.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Shedir Pharma Group
Historical stock prices
Current Share Price€4.88
52 Week High€4.98
52 Week Low€3.34
Beta0.72
1 Month Change0.41%
3 Month Change32.61%
1 Year Change7.96%
3 Year Change12.96%
5 Year Change-10.62%
Change since IPO-29.88%

Recent News & Updates

Shedir Pharma Group S.p.A.'s (BIT:SHE) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Nov 08
Shedir Pharma Group S.p.A.'s (BIT:SHE) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Recent updates

Shedir Pharma Group S.p.A.'s (BIT:SHE) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Nov 08
Shedir Pharma Group S.p.A.'s (BIT:SHE) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Shedir Pharma Group's (BIT:SHE) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 05
Shedir Pharma Group's (BIT:SHE) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Why Shedir Pharma Group's (BIT:SHE) Earnings Are Better Than They Seem

Oct 05
Why Shedir Pharma Group's (BIT:SHE) Earnings Are Better Than They Seem

Is Shedir Pharma Group (BIT:SHE) Using Too Much Debt?

Apr 06
Is Shedir Pharma Group (BIT:SHE) Using Too Much Debt?

What Type Of Returns Would Shedir Pharma Group's(BIT:SHE) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Dec 30
What Type Of Returns Would Shedir Pharma Group's(BIT:SHE) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Shareholder Returns

SHEIT PharmaceuticalsIT Market
7D0%2.0%1.2%
1Y8.0%1.0%16.6%

Return vs Industry: SHE exceeded the Italian Pharmaceuticals industry which returned -2.7% over the past year.

Return vs Market: SHE underperformed the Italian Market which returned 15% over the past year.

Price Volatility

Is SHE's price volatile compared to industry and market?
SHE volatility
SHE Average Weekly Movement5.4%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement4.3%
10% most volatile stocks in IT Market7.5%
10% least volatile stocks in IT Market2.6%

Stable Share Price: SHE has not had significant price volatility in the past 3 months compared to the Italian market.

Volatility Over Time: SHE's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200884Antonio Scalawww.shedirpharma.com

Shedir Pharma Group S.p.A., through its subsidiaries, engages in the research, formulation, development, and marketing of nutraceuticals, dermocosmetics, medical devices, and pharmaceutical products in Italy. It provides products for andrological, cardiovascular, dermatological, hematological, energy, gastrointestinal, gynecological, metabolic, neurological, dental, ophthalmic, osteoarticular, otologic, respiratory, and trichological diseases. The company offers its products through a network of sales agents, wholesalers, and pharmacies.

Shedir Pharma Group S.p.A. Fundamentals Summary

How do Shedir Pharma Group's earnings and revenue compare to its market cap?
SHE fundamental statistics
Market cap€55.45m
Earnings (TTM)€6.00m
Revenue (TTM)€60.96m

9.2x

P/E Ratio

0.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SHE income statement (TTM)
Revenue€60.96m
Cost of Revenue€42.05m
Gross Profit€18.91m
Other Expenses€12.91m
Earnings€6.00m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.53
Gross Margin31.02%
Net Profit Margin9.84%
Debt/Equity Ratio7.3%

How did SHE perform over the long term?

See historical performance and comparison

Dividends

3.6%

Current Dividend Yield

34%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/24 16:59
End of Day Share Price 2025/01/22 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shedir Pharma Group S.p.A. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gian GadiniBanca Akros S.p.A. (ESN)
Maria Di GradoKT & Partners Srl